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Abstract
Background: Acute HIV infection (prior to antibody seroconversion) represents a high-risk window for HIV transmission.
Development of a test to detect acute infection at the point-of-care is urgent.
Methods: Volunteers enrolled in a prospective study of HIV incidence in four African cities, Kigali in Rwanda and Ndola,
Kitwe and Lusaka in Zambia, were tested regularly for HIV by rapid antibody test and p24 antigen ELISA. Five subgroups of
samples were also tested by the Determine Ag/Ab Combo test 1) Antigen positive, antibody negative (acute infection); 2)
Antigen positive, antibody positive; 3) Antigen negative, antibody positive; 4) Antigen negative, antibody negative; and 5)
Antigen false positive, antibody negative (HIV uninfected). A sixth group included serial dilutions from a p24 antigen-
positive control sample. Combo test results were reported as antigen positive, antibody positive, or both.
Results: Of 34 group 1 samples with VL between 5x105 and .1.5x107 copies/mL (median 3.5x106), 1 (2.9%) was detected
by the Combo antigen component, 7 (20.6%) others were positive by the Combo antibody component. No group 2 samples
were antigen positive by the Combo test (0/18). Sensitivity of the Combo antigen test was therefore 1.9% (1/52, 95% CI 0.0,
9.9). One false positive Combo antibody result (1/30, 3.3%) was observed in group 4. No false-positive Combo antigen
results were observed. The Combo antigen test was positive in group 6 at concentrations of 80 pg/mL, faintly positive at 40
and 20 pg/mL, and negative thereafter. The p24 ELISA antigen test remained positive at 5 pg/mL.
Conclusions: Although the antibody component of the Combo test detected antibodies to HIV earlier than the comparison
antibody tests used, less than 2% of the cases of antigen-positive HIV infection were detected by the Combo antigen
component. The development of a rapid point-of-care test to diagnose acute HIV infection remains an urgent goal.
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Introduction
Acute HIV infection is the period following transmission of the
virus and before antibody seroconversion, during which the risk of
HIV transmission is high relative to chronic HIV infection [1].
Diagnosis of acute HIV infection remains a challenge. Acute
retroviral syndrome symptoms may not be present, and standard
detection methods such as antibody tests will fail to detect the new
infection [2,3]. Diagnostic aides such as risk score algorithms and
decision trees can provide some assistance to the clinician who
suspects acute HIV infection [4,5], but will likely miss some cases.
The use of HIV RNA tests is recommended in high incidence
areas [6], however, the cost, logistics and time needed for these
tests makes their widespread use impractical. The development of
a point-of-care, rapid test to detect acute HIV infection is therefore
important for rapid diagnosis and to allow the timely provision of
risk reduction counseling to prevent onward HIV transmission, as
well as the provision of treatment where the test and treat strategy
becomes available. In addition, in cross sectional surveys of HIV
prevalence with adequate sample size, identifying acute cases may
allow investigators to estimate HIV incidence [7,8].
The Determine HIV - 1/2 Ag/Ab Combo test (referred to as
the Combo test) is a rapid, visually read, qualitative immuno-
chromatographic test with separate indicators for both antibody
and p24 antigen results, allowing to distinguish acute from non-
acute HIV infection. We present results generated by testing
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e37154specimen panels from Rwandan and Zambian adults with or at
risk for acquiring HIV infection, and a panel of serially diluted p24
antigen-positive controls.
Methods
Volunteers are followed in a study of the sexual transmission of
HIV in Ndola, Kitwe and Lusaka, Zambia; and Kigali, Rwanda,
as described elsewhere [9,10]; briefly, HIV-uninfected volunteers
who are sexually active with a known HIV-infected partner are
followed either quarterly or monthly and receive risk reduction
counseling and HIV testing at each visit. Routine HIV screening
for HIV-uninfected volunteers is done with the Determine rapid
test (Abbot Laboratories, Chiba, Japan) and p24 ELISA (Coulter
p24 HIV-1 Antigen Assay from January 2002-April 2007 (Beck-
man Coulter, Inc. Fullerton, California, USA) and the Vironostika
HIV-1 p24 Antigen (BioMerieux bv, The Netherlands) from April
2007 to present. Confirmation of a positive Determine result was
done with both second and third line rapid tests (Capillus and
UniGold, Trinity Biotechnology). Additionally, acute infections
were confirmed using polymerase chain reaction (PCR) on the
HIV gp41 envelope region followed by genetic sequencing of the
virus. Previous work with the p24 ELISA in Africa showed that
the recommended assay cut-off led to a high rate of false positive
results [11]. We empirically established a more conservative cut-off
than either p24 ELISA or Vironostika p24 antigen assay package
inserts based on the incidence of false positive results within our
cohorts at the time of testing. The rate of false positive fell from
92% to 27% when the cut-offs we chose were used compared to
the manufacturers cut-offs (non-published data). Therefore, only
samples with results twice that of the recommended assay cut-off
value were read as p24 positive with the Vironostika p24 assay,
and three times the recommended cut-off for the Coulter p24
assay. Plasma samples were stored at -80?C and did not exceed
three freeze thaw cycles as recommended by the Determine HIV
K Ag/Ab Combo Test package insert. Volunteers with confirmed
HIV infection (Ag+/Ab2,A g +/Ab+,o rA g 2/Ab+) were invited
to join a study of early HIV infection; subjects were enrolled
within 90 days of estimated date of infection (EDI). All volunteers
provide informed consent, and these studies were approved by the
National Ethics Committee of Rwanda, the University of Zambia
Biomedical Research Ethics Committee, and the Emory Univer-
sity Institutional Review Board. All EC/IRBs are registered with
the U.S. Office of Human Research Protection.
The testing of specimens was conducted both at the field
laboratory in Lusaka, Zambia as well as the laboratory of Professor
Eric Hunter at Emory University’s Vaccine Center. The field
laboratory is Good Clinical Laboratory Practice (GCLP) accre-
dited by Qualogy Inc., externally audited three times per annum
by study sponsors, and participates in quarterly external quality
assurance (EQA) testing schemes for all diagnostic testing. The
testing of all specimens was done by three trained laboratory
scientists who were all in supervisory positions within the
organizations and each had greater than 4 years reading and
interpreting HIV rapid testing among the Rwandan and Zambian
populations. [12].
Plasma samples were retrospectively identified and tested by the
Determine HIV-1/2 Ag/Ab Combo test according to the package
insert (Combo test, Inverness Medical, Chiba, Japan). All results
were read visually by a trained laboratory technician. Samples that
produced a line in the results window that appeared to the eye
fainter than the control bar were recorded by the technician as
‘‘weakly positive’’ but were considered positive for all analyses, as
per the assay package insert. Examples of weakly positive results
can be seen in the Inverness Medical report on the Combo test
[13] and in [14]. Six groups of samples were tested:
1. Antigen positive, antibody negative samples from acutely HIV-
infected volunteers identified between 2002 and 2009, n=34.
2. Antigen positive, antibody positive samples from volunteers
with recent HIV infection. This group includes volunteers with
discrepant results across more than one antibody test (i.e., at
least one antibody test was positive and at least one was
negative), n=18.
3. Antigen negative, antibody positive samples from volunteers
with chronic HIV infection. Includes a convenience sample of
volunteers with known HIV infection arriving for routine study
visits, n=28.
4. Antigen negative, antibody negative samples from HIV-
uninfected volunteers. This group includes a convenience
sample of volunteers who did not show laboratory evidence of
HIV infection at this or their subsequent study visit, n=30.
5. P24 antigen ELISA positive, antibody negative samples from
HIV-uninfected volunteers (false positives), n=25.
6. A serially diluted p24-antigen control sample at a starting
concentration of 160 pg/mL (i.e., concentrations of 80, 40, 20,
10, 5, 2.5, 1.25 and 0.0625 pg/mL were tested), n=1.
All volunteers with positive p24 ELISA results were confirmed
as HIV-infected or as false positive by antibody testing at
subsequent weekly visits. Confirmatory antibody testing was done
using three rapid tests in accordance with both Rwanda and
Zambia’s national HIV testing algorithm. Two of three antibody
positive tests must be positive to yield a positive HIV antibody test
result. A total of 30/34 (88.2%) antigen positive, antibody negative
specimens were tested for the presence of HIV RNA (Roche
Amplicor, Roche Molecular Systems) on aliquots prepared at the
time of Determine HIV-1/2 Ag/Ab Combo testing. To conserve
specimens, the antigen positive, antibody negative samples were
diluted 20-fold with pooled and confirmed negative p24 antigen
and antibody plasma. Therefore, the lower limit of detection of the
assay was 8,000 copies/mL. The upper limit of the assay was
15x10
6 copies/mL. HIV-1 subtyping was done from amplified gag,
pol or gp41 sequences using the Recombination Identification
Program (http://www.hiv.lanl.gov/content/sequence/RIP/RIP.
html) as described previously [15].
The results of the Combo antigen test are compared to the
results of the p24 antigen ELISA to calculate test sensitivity.
Poisson exact methods were used to calculate 95% confidence
intervals. Analyses were conducted with Stata Statistical Software
(Release 11, College Station, TX, USA: StataCorp LP) and SAS
Statistical Software (SAS Institute Inc. 2009, Cary, NC).
Results
Study Population
A total of 135 plasma samples from 123 volunteers were tested,
including 99 volunteers from Lusaka, Zambia, 14 from the
Zambia’s Copperbelt (Kitwe and Ndola), and 10 from Kigali,
Rwanda (Table 1). Of the volunteers tested, 78 (63%) were HIV-
infected (groups 1-3), and 45 (37%) were HIV-uninfected controls
(groups 4 and 5). The volunteers included 58 (47%) women. Nine
volunteers provided multiple samples drawn sequentially, in-
cluding two with HIV infection. One volunteer with HIV infection
provided two samples (one Ag+/Ab2; and one Ag+/Ab+) and the
second seroconverting volunteer provided two samples (one Ag+/
Ab2; and one Ag2/Ab+). The remaining seven volunteers who
provided multiple samples were all from group 5 (p24 ELISA false
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three who provided three samples (Table 1). Subtype data were
available for 54/78 (69.2%) of the volunteers with HIV infection
(Table 1). In Zambia of the 45 for whom subtype was available, 44
(97.8%) were infected with subtype C, and 1 (2.2%) with a subtype
A/C recombinant virus. In Rwanda, 7/9 (77.8%) were infected
with subtype A1, and 2 (22.2%) with subtype C.
Combo Antigen and Antibody Results
Of 34 samples from acutely infected volunteers in group 1
(antigen positive, antibody negative), one sample (2.9%, from
a subtype-C infected volunteer) was antigen positive, antibody
negative by the Combo test, and seven (20.6%) additional samples
were antibody positive but antigen negative (Table 2). Of 18
samples with both detectable p24 antigen and antibody from
group 2, no samples were antigen positive and all were antibody
positive by the Combo test. Therefore, among all 52 HIV positive
samples with a positive antigen ELISA result, the sensitivity of the
Combo antigen test was 1.9% (95% confidence interval: 0.0, 9.9).
The single antigen positive result from the Combo test was weakly
positive, with the antigen band appearing fainter than the control
band upon visual inspection.
The univariate summary statistics for p24 antigen concentration
among all ELISA identified p24 positives and viral load values are
reported in Table 3. The difference in p24 antigen concentration
between groups 1 and 2 (Ag+/Ab2 and Ag+/Ab+) was not
statistically significant p=.1661. Likewise, the concentration of
p24 antigen in the 8 specimens that the rapid antigen/antibody
was able to identify (one Ag+ and seven Ab+) versus the 26 ELISA
p24 positive specimens that tested negative on the rapid assay did
not differ with significance, p=.9031.
Viral load data were available from 37 (71.2%) of the group 1
and 2 samples. The median HIV RNA concentration was 3.5x10
6
copies/mL, with 8 values above the assay upper limit of 15x10
6
copies/mL. The sample positive by Combo antigen had a viral
load of 1.1x10
7 copies/mL and was higher than 66% of the group
1 and 2 samples with viral load data. There was a strong
correlation between p24 antigen concentration and viral load for
Ag+Ab2 individuals (0.741, p,.0001) as well as combined
Ag+Ab2 and Ag+Ab+ (0.722, p,.0001).
Table 1. Study Population Characteristics.
Group 1:
Ag+ Ab2
Group 2:
Ag+Ab+
Group 3:
Ag2Ab+
Group 4:
Ag2Ab2
Group 5:
Ag False+Ab2
Characteristic N % N % N % N % N %
Total number of volunteers 34 100 18 100 28 100 30 100 15 100
Sex
Female 21 61.8 4 23.3 19 67.9 8 26.7 6 40
Male 13 38.2 14 77.7 9 32.1 22 73.3 9 60
Enrolment site
Kigali, Rwanda 5 14.7 4 22.2 0 – 0 – 1 7
Lusaka, Zambia 23 67.7 8 44.4 28 100 30 100 12 80
Copperbelt, Zambia 6 17.6 6 33.3 0 – 0 – 2 13
HIV-1 subtype
A1 4 11.8 3 16.7 0 – 0 – 0 –
C 29 85.3 15 83.3 4 14.3 0 – 0 –
A/C recombinant 1 2.9 0 – 0 – 0 –
Missing 0 – 0 – 24 85.7 0 – 0 –
Not Applicable 0 – 0 – 0 – 30 100 15 100
HIV-1 viral load*
Number tested 30 88.2 7 38.9 0 – 0 – 0 –
Median, (IQR) 6.8 (6.2,7.2) 6.2 (6.1,6.8)
Number of samples contributed**
1 34 100 18 100 28 100 30 100 8 47
2 0 –0 –0 – 0 – 4 3 3
3 0 –0 –0 – 0 – 3 2 0
Group 1: Antigen positive, antibody negative acute HIV infection (Ag+Ab2).
Group 2: Antigen positive, antibody positive early HIV infection (Ag+Ab+).
Group 3: Antigen negative, antibody positive chronic HIV infection (Ag2Ab+).
Group 4: Antigen negative, antibody negative volunteers without HIV infection (Ag2Ab2).
Group 5: Antigen false positive, antibody negative volunteers without HIV infection (Ag2Ab2).
Ag: p24 antigen, Ab: HIV antibody, weak pos: the respective assay indicator was fainter than the control indicator. This is considered ‘‘positive’’ in our analyses, as per the
package insert.
*Log10 transformed viral copies/mL.
**7/123 volunteers contributed more than one sample to their respective group from different dates (group 5) and 2 volunteers from group 1 contributed a second
sample; one to group 2 and the other to group 3.
doi:10.1371/journal.pone.0037154.t001
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volunteers without HIV infection were antigen-positive by the
Combo test. However one group 4 sample (3.3%) was antibody-
positive by the Combo test, a false positive result. In a comparison
of the Combo test antigen component to the ELISA antigen test,
both assays were run against serially diluted p24 antigen control
provided in the Vironostika HIV-1 Antigen ELISA kit; in which
the positive control is serial diluted with the kit’s negative control
per testing instructions (group 6). The reported optical density of
the serial p24 dilution was the average of duplicate runs. The
Combo antigen test remained positive to p24 antigen concentra-
tions of 20 pg/mL and the ELISA remained positive to 5pg/mL
(Table 4).
Discussion
In this prospective cohort of African adults infected with or at
high risk for HIV infection, the Determine Ag/Ab Combo test
detected only 8 of 34 (23.5%) persons with acute HIV infection.
Only one of these 8 positive Combo test results was scored as
antigen-positive, the remaining 7 were antibody-positive. Also, the
antigen component of the Combo test did not detect any of the 18
samples that were antigen- and antibody-positive in volunteers
with early HIV infection, and when tested against serially diluted
p24 antigen-positive controls, was not as sensitive as the p24
ELISA. While the antibody component of the Combo test was
able to detect antibodies to HIV before the rapid HIV tests used in
this report, the antigen component of the Combo test was much
less sensitive than the p24 antigen ELISA in detecting acute
infection in these subtype A and C plasma samples. The Combo
test package insert reports two analytical sensitivity studies one
which used an HIV Ag panel from the French Blood Establish-
ment and the second used purified HIV-1 p24 native protein. The
reported lower limits of p24 antigen concentration that could be
detected by the Combo assay were 25 pg/ml and 12.5 pg/ml
respectively [16]. Twenty one percent (11/52) of the acute
infections we identified with the p24 Antigen ELISA had
concentrations less than 25 pg/ml but of these 11, only 2 had
p24 Antigen concentrations less than 12 pg/ml and theoretically
should have been picked up by the Combo assay. The sole acute
infection that was detected by the Combo assay had a p24 antigen
concentration of 248.3 pg/ml. Recent work in Malawi, where the
HIV epidemic is primarily subtype C, also found that the Combo
test failed to detect acute HIV infection. The authors report that 8
Table 2. Performance of the Determine Ag/Ab Combo test.
Group 1:
Ag+ Ab2
Group 2:
Ag+Ab+
Group 3:
Ag2Ab+
Group 4:
Ag2Ab2
Group 5: Ag False+
Ab2
Determine Ag/Ab
Combo test results N % N % N % N % N %
Total number of samples 34 100 18 100 28 100 30 100 25 100
Ag negative, Ab negative 26 76.5 0 0 0 0 29 96.7 25 100
Ag positive, Ab positive 0 0 0 0 0 0 0 0 0 0
Ag positive, Ab negative 0 0 0 0 0 0 0 0 0 0
Ag weak pos, Ab negative 1 2.9 0 0 0 0 0 0 0 0
Ag negative, Ab positive 1 2.9 15 83.3 28 100 0 0 0 0
Ag negative, Ab weak pos 6 17.6 3 16.7 0 0 1 3.3 0 0
Group 1: Antigen positive, antibody negative acute HIV infection (Ag+Ab2).
Group 2: Antigen positive, antibody positive early HIV infection (Ag+Ab+).
Group 3: Antigen negative, antibody positive chronic HIV infection (Ag2Ab+).
Group 4: Antigen negative, antibody negative volunteers without HIV infection (Ag2Ab2).
Group 5: Antigen false positive, antibody negative volunteers without HIV infection (Ag2Ab2).
Ag: p24 antigen, Ab: HIV antibody, weak pos: the respective assay indicator was fainter than the control indicator. This is considered ‘‘positive’’ in our analyses, as per the
package insert.
doi:10.1371/journal.pone.0037154.t002
Table 3. ELISA p24 Antigen Concentration and Viral Load Summary Statistics.
p24 Ag Concentration (pg/ml)
Summary
Statistics Groups 1 & 2 Group 1
Group 1 Subset
Rapid Test NEG
Group 1 Subset Rapid
Test POS (Ag or Ab) Group 2 Viral Load (copies/ml)
N 52 34 26 8 18 37
Mean 126.01 138.7 136.2 146.8 102.1 7,013,211
Median 94.1 140.4 140.4 162 50.4 6,316,740
IQR (75%,25%) (201.2,32.7) (203.5,48.4) (193,51) (267.8,14.4) (152.7,15.7) (12950000, 1706540)
Min,Max (8.2,457.8) (8.2,457.9) (14.2,457.9) (8.2,277.7) (10.4,351.2) (545720,15000001*)
*Upper limit of detection for the VL assay =15,000,000, any observation that exceeded 15,000,000 recorded as 15,000,001.
Group 1: Antigen positive, antibody negative i.e. acute HIV infection (Ag+ Ab2).
Group 2: Antigen positive, antibody positive i.e. early HIV infection (Ag+ Ab+).
doi:10.1371/journal.pone.0037154.t003
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component of the Combo test (although 2 were detected by the
antibody component), and that 14 false positive Combo antigen
results were observed in 838 HIV-uninfected persons, for a sensi-
tivity of 0.00 and a specificity of 0.98 [17]. A report from France to
evaluate the sensitivity of five rapid HIV tests in a health care
setting found the Combo test did not detect p24 antigen in two
volunteers with recent HIV infection. The concentration of p24
antigen in the plasma of one volunteer was 380pg/mL, and
undetectable in the other [18]. In contrast, the assay has been
tested in San Francisco, and correctly identified all persons with
chronic infection, and 7/9 persons with acute HIV infection [19].
Another recent report found the sensitivity of the Combo test in
a bank of acute HIV infection specimens from Holland to be
86.6% (32/39 samples, 95% CI: 76.0, 93.7). However two of the
32 samples were reactive in the antibody component only and no
subtype or demographic data are given. The authors of this work
also report being able to detect antigen in cell supernatants from
subtypes A, B, C, D, CRF_01AE, CRF01_AG, G, G/H, J, G/A,
and K (3–5 samples of each) diluted in negative human plasma,
however the concentration of p24 antigen in each sample was not
reported [20].
While the package insert for the Combo test states that
specimens that have been freeze-thawed more than three times
should not be used for testing, a majority of our samples tested had
not been thawed more than once. Moreover, the specimen in this
report that was antigen-positive by both p24 antigen ELISA and
Combo test was 3.5 years old at the time of testing. None of the 31
more recent group 1 or 2 samples were detected by the antigen
component of the Combo test, including four samples that were
drawn within 2 months of testing. Finally, all viral load assays on
group 1 and 2 samples were performed on aliquots processed in
parallel to those tested in the Combo test, and so it is unlikely that
freeze-thawing of samples contributed to the lack of reactivity in
this assay.
Reduced performance may have been related to the circulating
strains of HIV. Although this assay reportedly detected p24
antigen in cell supernatant of viral cultures of non-B subtype HIV
[20], we were unable to reproduce these results using plasma
samples from study volunteers infected with subtype A and
subtype C HIV-1. The single positive antigen results from the
Combo test was from a volunteer infected with subtype C HIV-1.
Strengths of this report include the prospective study design,
and the availability of HIV PCR results. All volunteers were
enrolled in a prospective study of HIV incidence in HIV-
discordant couples. At each visit, volunteers are given risk-
reduction counseling and testing for HIV infection. Despite
counseling, HIV transmission continued to occur albeit at
a reduced frequency and monthly follow-up facilitated detection
of HIV infection prior to HIV seroconversions [21]. Because all
volunteers were followed up, we were able to confirm their HIV
status at follow up visits. A number of instances of p24 positive
ELISA results were observed on repeated-testing of volunteers
without HIV infection (manuscript in preparation). These pro-
vided the samples for group 5. All volunteers with acute or early
HIV infection were eventually confirmed with detection of HIV by
PCR, and 81% of volunteers from group 1 and 2 had viral load
data available from that visit. Viral load and p24 antigen
concentrations are typically positively correlated [22,23]. Because
group 1 and 2 samples came from acute and early HIV infection,
viral load was very high (frequently exceeding 10
7 copies/mL).
Indeed, one third of the samples with data had a higher viral load
than the sample that was Combo antigen positive, and yet none of
these scored positive.
Although the package insert instructs the user to score a faintly
visible band as a positive result, these weak positive results may be
difficult to read [13] and training is important. The only antigen
positive result we observed was fainter than the control band, as
was 10 of 54 (18.5%) of the antibody positive results we reported.
In our experience with HIV antibody rapid tests, a weak positive
result can be indicative of a false positive test result [12], and 1 of
10 (10%) of the observed weak positive antibody results in this
report were false positive; 44 of 44 (100%) of the Combo antibody
positives without a weakly positive band were true seroconver-
sions. Another study considers weak positive as a doubtful result
and used an algorithm that required retesting of samples. This
study found that of the 2.3% of the results classified as weakly
positive results, 46% were resolved as negative [12].
We found the Combo antigen component of the Determine test
to be unsatisfactory as a point-of-care test for the rapid diagnosis
of acute HIV infection in this predominantly subtype C sample of
study volunteers. Given the importance of proper diagnosis of
acute HIV infection, a critical time of increased infectivity, the
development of rapid diagnosis tools remains an urgent priority.
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